Ivabradine for heart failure: regulatory differences in Europe and United States

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):119-121. doi: 10.1093/ehjcvp/pvz006.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cardiovascular Agents / therapeutic use*
  • Drug Approval / legislation & jurisprudence*
  • Europe
  • Evidence-Based Medicine / legislation & jurisprudence*
  • Government Regulation*
  • Healthcare Disparities / legislation & jurisprudence*
  • Heart Failure / diagnosis
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Humans
  • Ivabradine / adverse effects
  • Ivabradine / therapeutic use*
  • Patient Safety
  • Policy Making
  • Risk Assessment
  • Risk Factors
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence*

Substances

  • Cardiovascular Agents
  • Ivabradine